Literature DB >> 25627814

Estimated numbers of patients with liver disease related to hepatitis B or C virus infection based on the database reconstructed from medical claims from 2008 to 2010 in Japan.

Masayuki Ohisa1, Yuki Kimura1, Junko Matsuo1, Tomoyuki Akita1, Tomoki Sato1, Toshihiko Matsuoka1, Kazuaki Sakamune1, Keiko Katayama1, Son Huy Do1, Yuzo Miyakawa2, Junko Tanaka1.   

Abstract

AIM: To estimate the number of patients with liver-related diseases classified by hepatitis viruses (HBV, HCV) based on the information from re-coded medical claims including several diagnosed diseases.
METHODS: We analyzed reimbursement data provided by health insurance societies for 2.1 million individuals during 2008-2010. Database information of employees and their families aged under 65 years employees with hepatitis-related disease was extracted, the 1-year period prevalence was calculated, and then number of patients with liver disease related to HBV and HCV by sex and age groups, respectively, was estimated.
RESULTS: The estimated number of patients were almost equivalent during 2008-2010. As for HBV and HCV, the estimated numbers of patients with chronic hepatitis (CH) in a year ranged 192 641-226 601 and 282 438-306 877, respectively.
CONCLUSION: In the 2008 Patient Survey in Japan, the number of patients was estimated by the main disease in one patient, even though the patient was diagnosed with several diseases. Based on the database with hepatitis-related diseases after evaluating several diagnosed diseases from medical claims, the estimation method and protocol may minimize the disadvantage of medical claim analysis, and is useful for patients, especially asymptomatic carriers and those with CH which had been underestimated in the 2008 Patient Survey.
© 2015 The Japan Society of Hepatology.

Entities:  

Year:  2015        PMID: 25627814     DOI: 10.1111/hepr.12497

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  7 in total

1.  Adherence to antihypertensive medication and its predictors among non-elderly adults in Japan.

Authors:  Shiori Nishimura; Hiraku Kumamaru; Satoshi Shoji; Mitsuaki Sawano; Shun Kohsaka; Hiroaki Miyata
Journal:  Hypertens Res       Date:  2020-04-20       Impact factor: 3.872

Review 2.  Factors associated with the response to interferon-based antiviral therapies for chronic hepatitis C.

Authors:  Hirayuki Enomoto; Shuhei Nishiguchi
Journal:  World J Hepatol       Date:  2015-11-18

3.  Vitamin D-Deficient Rickets in Japan.

Authors:  Mitsuko Itoh; Jun Tomio; Satoshi Toyokawa; Mayuko Tamura; Tsuyoshi Isojima; Sachiko Kitanaka; Yasuki Kobayashi
Journal:  Glob Pediatr Health       Date:  2017-06-01

4.  Database analysis of patients with hepatocellular carcinoma and treatment flow in early and advanced stages.

Authors:  Keishi Akada; Noriyuki Koyama; Shigeru Taniguchi; Yuji Miura; Ken Aoshima
Journal:  Pharmacol Res Perspect       Date:  2019-06-20

Review 5.  Countermeasures against viral hepatitis B and C in Japan: An epidemiological point of view.

Authors:  Junko Tanaka; Tomoyuki Akita; Ko Ko; Yoshihiko Miura; Masahiro Satake
Journal:  Hepatol Res       Date:  2019-08-22       Impact factor: 4.288

6.  Anisakiasis Annual Incidence and Causative Species, Japan, 2018-2019.

Authors:  Hiromu Sugiyama; Mitsuko Shiroyama; Ikuyo Yamamoto; Takashi Ishikawa; Yasuyuki Morishima
Journal:  Emerg Infect Dis       Date:  2022-10       Impact factor: 16.126

7.  Process quality of diabetes care under favorable access to healthcare: a 2-year longitudinal study using claims data in Japan.

Authors:  Hirokazu Tanaka; Jun Tomio; Takehiro Sugiyama; Yasuki Kobayashi
Journal:  BMJ Open Diabetes Res Care       Date:  2016-09-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.